The medical policy represents more than the addition of a new payer. It begins to address one of the principal constraints on U.S. commercial scale and creates a pathway to convert established clinical adoption into broader reimbursed utilization.
SciBase has already established a strong commercial momentum in the United States without broad private payer reimbursement. The addition of coverage expands the number of dermatology practices and patients that can get access to Nevisense.
The decision from the first private payer marks a major milestone in SciBase's U.S. commercialization strategy and changes the reimbursement landscape for Nevisense.
"We have continued to strengthen Nevisense's position within both the skin cancer and skin barrier segments during both this and the last year. Several clinical studies and collaborations validate the value Nevisense adds and we see increased interest in the US as well as in other markets.," said Pia Renaudin CEO of SciBase. " The first medical policy is a defining milestone for SciBase and an important step forward in the development of our U.S. business and means we can now start scaling and thus improve patients' lives."
Pia adds: "This is an important step towards reaching our ambition to become the global leader in non-invasive, high-precision skin assessment for cancer detection and skin barrier evaluation, with the ambition of capturing a significant share of a $1billion market".
Nevisense is a non-invasive technology and clinicians get an objective, high-precision reading that can help diagnose skin cancer earlier and assess the skin barrier more reliably. For patients, that means fewer unnecessary procedures and for clinics, faster decisions.
Skin cancer is the most common cancer worldwide, and interest in skin barrier health keeps growing. Combined, the segments are worth an estimated $1 billion. With our business model of recurring revenue, we underpin the 75% gross margin target and keep the growth sustainable.
What the policy covers
Under the policy, EIS is considered medically necessary when a dermatologist is evaluating a clinically atypical suspicious pigmented lesion and is considering a biopsy.
The procedure is reported with CPT code 0658Tand the key criteria include:
Melanoma is part of the differential diagnosis
The lesion is on the trunk or extremities and measures 2 mm to 20 mm
The patient is 18 or older
The lesion is not on a mucosal surface, palm, sole or nail, and is not ulcerated, bleeding or recently traumatized
The device is FDA-approved and used by a dermatologist trained in clinical and dermoscopic evaluation of pigmented lesions
In support of its position, the payer cites the NCCN Clinical Practice Guidelines for Cutaneous Melanoma (Version 2.2026), which list EIS among technologies that may aid detection of new primary melanoma, and American Academy of Dermatology guidance on emerging noninvasive diagnostics.
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
In the study healthy subjects will either be exposed to common skin products that contain sodium lauryl sulfate (SLS), bedding and clothing made of synthetic fibers, or pure contactants free of SLS and apparel/linen made from natural fibers (100% cotton). The effects of these exposures will be measured and compared using skin impedance (electrical impedance spectroscopy, EIS) as a marker of skin barrier dysfunction. Skin impedance devices transmit electrical signals at different frequencies that sense opposition to the electrical flow thus reflecting the barrier functional status of the skin.
The key highlights of the study are:
NIH has selected skin impedance, measured using SciBase's EIS technology, as the primary endpoint for assessing the impact of environmental exposures on skin barrier function in the THREAT study.
The study involves 80 healthy volunteers and investigates the effects of everyday exposures, including detergents, personal care products and synthetic textiles.
EIS will be used to monitor changes in skin barrier function over time, alongside molecular, microbiome and inflammatory biomarkers.
The study highlights the scientific relevance of EIS as an objective method for assessing skin barrier function, with potential applications in dermatology, cosmetic research and skin care product development.
"We are pleased that our Nevisense technology has been selected for this important NIH-led research initiative. The use of skin impedance as a primary endpoint highlights the scientific relevance of EIS in assessing skin barrier function. We believe this represents an important step in expanding the role of our technology in dermatology and skin health research," said Pia Renaudin, CEO of SciBase.
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
The decision marks a major milestone in SciBase's U.S. commercialization strategy and changes the reimbursement landscape for Nevisense. For the first time, eligible use of the technology can move from a predominantly cash-pay model into covered care through a major U.S. private insurer, reducing one of the most significant barriers to broader clinical adoption.
SciBase has already established strong commercial momentum in the United States without broad private payer reimbursement. The addition of coverage introduces a new growth driver to an existing business, expanding the number of dermatology practices and patients that can access Nevisense within a reimbursed model.
"This is a defining milestone for SciBase and an important step forward in the development of our U.S. business," said Pia Renaudin, CEO of SciBase. " Highmark coverage begins to remove one of the most important barriers to scale and creates the opportunity to reach a substantially larger portion of the U.S. market. Reimbursement now becomes an additional driver of growth in a business where demand for our technology has already been established."
The United States is SciBase's largest commercial opportunity. Approximately 6,500 to 7,000 private dermatology clinics operate in the U.S., with around 6,000 considered relevant for Nevisense, and an estimated 4 to 4.5 million skin biopsies are performed annually.
The Highmark decision represents more than the addition of a new payer. It begins to address one of the principal constraints on U.S. commercial scale and creates a pathway to convert established clinical adoption into broader reimbursed utilization.
Highmark, together with its Blue-branded affiliates, is one of the largest Blue Cross Blue Shield affiliated organizations in the United States, serving over 7 million members across multiple states.
For dermatologists, reimbursement can reduce the financial barrier to incorporating Nevisense into care for eligible patients while expanding patient access to objective, non-invasive technology that can support the assessment of suspicious skin lesions.
SciBase will continue its engagement across the U.S. payer market while expanding commercial activity in geographies where reimbursement is available.
What the policy covers
Under the policy, Highmark considers EIS medically necessary when a dermatologist is evaluating a clinically atypical suspicious pigmented lesion and is considering a biopsy.
The procedure is reported with CPT code 0658Tand the key criteria include:
Melanoma is part of the differential diagnosis
The lesion is on the trunk or extremities and measures 2 mm to 20 mm
The patient is 18 or older
The lesion is not on a mucosal surface, palm, sole or nail, and is not ulcerated, bleeding or recently traumatized
The device is FDA-approved and used by a dermatologist trained in clinical and dermoscopic evaluation of pigmented lesions
The policy applies to all Highmark commercial insured lines of business and to self-funded (ASO) employer groups that elect it. In support of its position, Highmark cites the NCCN Clinical Practice Guidelines for Cutaneous Melanoma (Version 2.2026), which list EIS among technologies that may aid detection of new primary melanoma, and American Academy of Dermatology guidance on emerging noninvasive diagnostics.
This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 09:00 AM CEST on October 14, 2026.
Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.
Conversion of BTA into shares
The Rights Issue was registered with the Swedish Companies Registration Office on 8 October 2026. Through the Rights Issue, 3,834,487 new shares were issued, and the BTA allotted in the Rights Issue will now be converted into shares. The last day of trading in BTA on Nasdaq First North Growth Market is Friday 16 October 2026. The record date with Euroclear Nordics AB is Tuesday 20 October 2026, and the new shares are expected to be available in the respective securities accounts and custody accounts on Thursday 22 October 2026.
The conversion of BTA into shares takes place automatically and without any specific notification from Euroclear Nordics AB. Holders of nominee-registered holdings will be informed of the conversion in accordance with the procedures of their respective nominee.
Number of shares and share capital
Following the registration of the Rights Issue and the directed set-off issue of 60,000 shares to the guarantor resolved by the Board of Directors on 7 October 2026, the number of shares in SciBase amounts to 14,119,787 shares and the share capital to SEK 70,598,935.
Advisers
SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.
SciBase is a global medical technology company specialising in early detection and prevention within dermatology. SciBase develops, manufactures and commercialises Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to enhance diagnostic accuracy and ensure proactive skin health management.
Our commitment is to minimise patient suffering, enabling physicians to improve and save lives through early detection and intervention and to reduce healthcare costs.
SciBase is built on more than 20 years of research at Karolinska Institutet in Stockholm and is at the forefront of advances in dermatology.
The Company has been listed on Nasdaq First North Growth Market since 2 June 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Read more at www.scibase.com. For press releases and financial reports, visit: https://investors.scibase.se.
Important information:
The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law, and persons in the jurisdictions in which this press release has been made public or distributed should inform themselves about, and comply with, such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with the applicable rules in each jurisdiction.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus has been prepared in connection with the Rights Issue. The Company has prepared and published an information document in respect of the Rights Issue, which is available on the Company's website (https://investors.scibase.se). No prospectus or information document will be prepared or published in connection with the set-off issue.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the "Securities Act") and may not be offered or sold in the United States absent registration, or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction in which such release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require registration, or measures other than those required under Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not relate to historical facts and events, as well as statements relating to the future which, for example, contain expressions such as "anticipates", "intends", "may", "will", "should", "estimates", "believes", "could", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results, financial position, cash flows, plans and expectations regarding the company's operations and management, future growth and profitability, as well as the general economic and regulatory environment and other circumstances affecting the company, many of which are in turn based on further assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which, individually or together, may be material to the company's results or its ability to conduct its operations. Although the Company considers that these assumptions were reasonable when they were made, they are by their nature subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and that may be beyond the Company's control. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Prospective investors should therefore not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly recommended to read those sections of the information document that contain a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements in this press release are valid only as at the date of this press release and may be subject to change without notice.
Following the completed recalculation, SciBase can announce that the number of shares that each warrant of series TO 2 entitles to subscribe for and the subscription price per share has changed in accordance with the following. Following the recalculation, one (1) warrant of series TO 2 entitles the holder to subscribe for 0.01 shares at a subscription price of SEK 37.47 per share.
Following the recalculation, one (1) warrant of series TO 2 entitles the holder to subscribe for 0.01 new shares in the Company during the period from and including on 3 April 2029, until and including 17 April 2029.
The terms and conditions for the warrants, including potential adjustments due to future share issues, are available on the Company's website.
The information was submitted for publication, through the agency of the contact person set out above, on October 7, 2026 at 08.00 CET.
Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected]
About SciBase:
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.
Background
On 3 September 2026, the Board of Directors of SciBase resolved on the Rights Issue, the outcome of which was announced on 1 October 2026. In connection with the Rights Issue, Bergs Securities provided a guarantee commitment of approximately SEK 24.2 million. For the guarantee commitment, guarantee compensation is payable amounting to 10 percent of the guaranteed amount in cash or, alternatively, 12 percent of the guaranteed amount in newly issued shares in the Company at a subscription price corresponding to the subscription price in the Rights Issue. The guarantee compensation shall, according to the guarantee agreement, be paid in full or in part in either form.
Bergs Securities has notified the Company that it wishes to receive part of the guarantee compensation, totalling SEK 0.9 million, in the form of newly issued shares.
The Compensation Issue
In order to fulfil the Company's contractual obligation towards the guarantor, the Board of Directors has today, pursuant to the authorisation granted by the Annual General Meeting on 19 May 2026, resolved on the Compensation Issue. The subscription price amounts to SEK 15 per share, which corresponds to the subscription price in the Rights Issue. Payment for the shares is made by way of set-off against part of Bergs Securities' claim for guarantee compensation of SEK 0.9 million. All shares in the Compensation Issue have been subscribed for and allotted.
Reasons for the deviation from the shareholders' preferential rights
The reason for the deviation from the shareholders' preferential rights is to fulfil the Company's obligation towards Bergs Securities under the guarantee agreement entered into in connection with the Rights Issue. The Board of Directors considers it to be in the interest of the Company and its shareholders that part of the guarantee compensation is paid in the form of newly issued shares rather than in cash, as the Company thereby retains cash that can be used in its operations. The terms of the guarantee compensation, including the possibility to receive the compensation in newly issued shares and the maximum number of shares that could be issued, were announced in connection with the resolution on the Rights Issue on 3 September 2026.
The subscription price in the Compensation Issue was determined through arm's length negotiations between the Company and Bergs Securities when the letter of intent regarding the guarantee commitment was entered into, and corresponds to the subscription price in the Rights Issue. Against this background, the Board of Directors considers the subscription price to be on market terms.
Number of shares, share capital and dilution
Through the Compensation Issue, the number of shares in SciBase increases by 60,000 shares, from 14,059,787 shares to 14,119,787 shares, and the share capital increases by SEK 300,000, from SEK 70,298,935 to SEK 70,598,935, calculated following registration of the Rights Issue with the Swedish Companies Registration Office. The Compensation Issue entails a dilution of approximately 0.4 percent of the number of shares and votes in the Company.
Advisers
SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.
SciBase is a global medical technology company specialising in early detection and prevention within dermatology. SciBase develops, manufactures and commercialises Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to enhance diagnostic accuracy and ensure proactive skin health management.
Our commitment is to minimise patient suffering, enabling physicians to improve and save lives through early detection and intervention and to reduce healthcare costs.
SciBase is built on more than 20 years of research at Karolinska Institutet in Stockholm and is at the forefront of advances in dermatology.
The Company has been listed on Nasdaq First North Growth Market since 2 June 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Read more at www.scibase.com. For press releases and financial reports, visit: https://investors.scibase.se.
Important information:
The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law, and persons in the jurisdictions in which this press release has been made public or distributed should inform themselves about, and comply with, such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with the applicable rules in each jurisdiction.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus has been prepared in connection with the Rights Issue. The Company has prepared and published an information document in respect of the Rights Issue, which is available on the Company's website (https://investors.scibase.se). No prospectus or information document will be prepared or published in connection with the Compensation Issue.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the "Securities Act") and may not be offered or sold in the United States absent registration, or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction in which such release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require registration, or measures other than those required under Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not relate to historical facts and events, as well as statements relating to the future which, for example, contain expressions such as "anticipates", "intends", "may", "will", "should", "estimates", "believes", "could", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results, financial position, cash flows, plans and expectations regarding the company's operations and management, future growth and profitability, as well as the general economic and regulatory environment and other circumstances affecting the company, many of which are in turn based on further assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which, individually or together, may be material to the company's results or its ability to conduct its operations. Although the Company considers that these assumptions were reasonable when they were made, they are by their nature subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and that may be beyond the Company's control. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Prospective investors should therefore not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly recommended to read those sections of the information document that contain a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements in this press release are valid only as at the date of this press release and may be subject to change without notice.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.
"We are very grateful for the confidence that shareholders and new investors have shown in us. The raised capital enables the Company to continue to build its position in melanoma diagnostics in the United States, where SciBase is approaching an important milestone in the form of reimbursement, and to take the next step in the collaboration with Castle Biosciences", says Pia Renaudin, CEO of SciBase.
"The broad support from our shareholders is a sign of strength. With strengthened finances and an organisation that is performing well in both the United States and Germany, SciBase is well equipped for the next phase and the upcoming CEO transition", says Jesper Høiland, Chairman of the Board of SciBase.
Outcome of the Rights Issue
The subscription period in the Rights Issue ran from and including 15 September 2026 up to and including 29 September 2026. The outcome shows that 2,681,085 shares were subscribed for with the support of subscription rights, corresponding to approximately SEK 40.2 million or approximately 69.9 percent of the Rights Issue. In addition, 133,116 shares were subscribed for without the support of subscription rights, corresponding to approximately SEK 2.0 million or approximately 3.5 percent of the Rights Issue. In total, 2,814,201 shares were thus subscribed for with and without the support of subscription rights, corresponding to approximately SEK 42.2 million or approximately 73.4 percent of the Rights Issue. The remaining 1,020,286 shares, corresponding to approximately SEK 15.3 million and approximately 26.6 percent of the Rights Issue, are allotted to Bergs Securities in accordance with the guarantee commitment entered into. The Rights Issue is thereby fully subscribed.
The subscription price in the Rights Issue was SEK 15 per share. Through the Rights Issue, SciBase will receive approximately SEK 57.5 million before deduction of issue costs, which are estimated to amount to approximately SEK 4.8 million (including any cash guarantee compensation, which may amount to a maximum of approximately SEK 2.4 million). The net proceeds enable continued commercialisation activities with a focus on the US market.
Notification of allotment
Allotment of shares subscribed for without the support of subscription rights has been made in accordance with the allotment principles set out in the information document published by the Company on 14 September 2026. Notification of allotment will be made through the distribution of contract notes. Subscribed and allotted shares shall be paid for in cash in accordance with the instructions on the contract note. Investors who subscribed through a nominee will receive notification of allotment in accordance with the procedures of their respective nominee. Only those who have been allotted shares will be notified.
Trading in BTA and new shares
Trading in BTA (paid subscribed shares) will continue on Nasdaq First North Growth Market until the Rights Issue has been registered with the Swedish Companies Registration Office. The last day of trading in BTA is expected to be on or around 16 October 2026, after which BTA will be converted into shares without specific notification from Euroclear Nordics AB.
Compensation to the guarantor
In connection with the Rights Issue, Bergs Securities has provided a guarantee commitment of approximately SEK 24.2 million. For the guarantee commitment, guarantee compensation is payable amounting to 10 percent of the guaranteed amount in cash or, alternatively, 12 percent of the guaranteed amount in newly issued shares in the Company. The subscription price for shares issued as guarantee compensation shall be set at SEK 15 per share, corresponding to the subscription price in the Rights Issue.
Bergs Securities shall, no later than five (5) banking days after the end of the subscription period, notify the Company of the extent to which the guarantee compensation is to be paid in cash and in the form of newly issued shares, respectively. The guarantee compensation may be paid in full or in part in either form. Any resolution on a directed issue of shares as guarantee compensation will be announced through a separate press release.
Number of shares, share capital and dilution
Through the Rights Issue, the number of shares in SciBase increases by 3,834,487 shares, from 10,225,300 shares to 14,059,787 shares, and the share capital increases by SEK 19,172,435, from SEK 51,126,500 to SEK 70,298,935, corresponding to a dilution of approximately 27 percent of the total number of shares and votes in the Company following registration of the new shares with the Swedish Companies Registration Office.
Should the guarantee compensation be paid in full in the form of newly issued shares, the number of shares will increase by a further maximum of 193,669 shares and the share capital by a maximum of SEK 968,345, corresponding to an additional dilution of approximately 1.4 percent.
Advisers
SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.
For further information, please contact:
Jesper Høiland, Chairman of the Board, telephone +45 612 207 30
SciBase is a global medical technology company specialising in early detection and prevention within dermatology. SciBase develops, manufactures and commercialises Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to enhance diagnostic accuracy and ensure proactive skin health management.
Our commitment is to minimise patient suffering, enabling physicians to improve and save lives through early detection and intervention and to reduce healthcare costs.
SciBase is built on more than 20 years of research at Karolinska Institutet in Stockholm and is at the forefront of advances in dermatology.
The Company has been listed on Nasdaq First North Growth Market since 2 June 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Read more at www.scibase.com. For press releases and financial reports, visit: https://investors.scibase.se.
Important information:
The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law, and persons in the jurisdictions in which this press release has been made public or distributed should inform themselves about, and comply with, such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with the applicable rules in each jurisdiction.
The availability of the Rights Issue to holders not resident in Sweden may be affected by the legislation of the relevant jurisdiction in which they are located. Holders not resident in Sweden should inform themselves about, and comply with, all applicable laws and regulations.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus has been prepared in connection with the Rights Issue. The Company has prepared and published an information document in respect of the Rights Issue, which is available on the Company's website (https://investors.scibase.se).
This press release does not identify, and does not purport to identify, any risks (direct or indirect) that may be associated with an investment in the Company. The information in this press release is intended only to describe the background to the Rights Issue and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information in this press release.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the "Securities Act") and may not be offered or sold in the United States absent registration, or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction in which such release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require registration, or measures other than those required under Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not relate to historical facts and events, as well as statements relating to the future which, for example, contain expressions such as "anticipates", "intends", "may", "will", "should", "estimates", "believes", "could", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results, financial position, cash flows, plans and expectations regarding the company's operations and management, future growth and profitability, as well as the general economic and regulatory environment and other circumstances affecting the company, many of which are in turn based on further assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which, individually or together, may be material to the company's results or its ability to conduct its operations. Although the Company considers that these assumptions were reasonable when they were made, they are by their nature subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and that may be beyond the Company's control. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Prospective investors should therefore not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly recommended to read those sections of the information document that contain a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements in this press release are valid only as at the date of this press release and may be subject to change without notice.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.
Subscription undertakings and the Guarantee Commitment
Under the Guarantee Intention, which was entered into in connection with the Board of Directors' resolution on the Rights Issue on 3 September 2026, Bergs Securities could, up until the expiry of the subscription period in the Rights Issue, fulfil the Guarantee Intention by delivering a guarantee confirmation, whereupon a binding guarantee commitment arises. SciBase has today, on 25 September 2026, received such guarantee confirmation from Bergs Securities.
The Guarantee Commitment means that Bergs Securities has undertaken to subscribe for shares in the Rights Issue that are not subscribed for with or without the support of subscription rights, up to an amount of approximately SEK 24.2 million. Allotment will be made in accordance with the allotment principles announced on 3 September 2026. In support of the Guarantee Commitment, Bergs Securities has entered into sub-guarantee agreements with a consortium of investors corresponding to the entire Guarantee Commitment.
The guarantee compensation and the other terms of the Guarantee Commitment are unchanged from those set out in the press release published by the Company on 3 September 2026.
Several existing shareholders, including Ribbskottet AB, Castle Biosciences Inc, Haga Gruppen Holding AB, Life Science Invest Fund 1 ApS and Praktikerinvest AB, as well as members of the Company's Board of Directors and management, have previously entered into subscription undertakings in an aggregate amount of approximately SEK 33.3 million, corresponding to approximately 58 percent of the Rights Issue. No compensation is payable for the subscription undertakings.
The subscription undertakings and the Guarantee Commitment amount in aggregate to approximately SEK 57.5 million, corresponding to 100 percent of the Rights Issue. Neither the subscription undertakings nor the Guarantee Commitment are secured by bank guarantee, blocked funds, pledge or similar arrangements.
The Rights Issue in brief
The subscription price is SEK 15 per share. Shareholders who were registered in the share register maintained by Euroclear Nordics AB on the record date of 10 September 2026 received one (1) subscription right for each share held. Eight (8) subscription rights entitle the holder to subscribe for three (3) new shares.
The subscription period runs from and including 15 September 2026 up to and including 29 September 2026.
Trading in subscription rights on Nasdaq First North Growth Market took place up to and including 24 September 2026.
Trading in BTA (paid subscribed shares) on Nasdaq First North Growth Market continues until on or around 16 October 2026.
The outcome of the Rights Issue is expected to be announced on or around 1 October 2026.
An information document relating to the Rights Issue is available on the Company's website, https://investors.scibase.se.
Advisers
SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.
SciBase is a global medical technology company specialising in early detection and prevention within dermatology. SciBase develops, manufactures and commercialises Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to enhance diagnostic accuracy and ensure proactive skin health management.
Our commitment is to minimise patient suffering, enabling physicians to improve and save lives through early detection and intervention and to reduce healthcare costs.
SciBase is built on more than 20 years of research at Karolinska Institutet in Stockholm and is at the forefront of advances in dermatology.
The Company has been listed on Nasdaq First North Growth Market since 2 June 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Read more at www.scibase.com. For press releases and financial reports, visit: https://investors.scibase.se.
Important information:
The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law, and persons in the jurisdictions in which this press release has been made public or distributed should inform themselves about, and comply with, such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with the applicable rules in each jurisdiction.
The availability of the Rights Issue to holders not resident in Sweden may be affected by the legislation of the relevant jurisdiction in which they are located. Holders not resident in Sweden should inform themselves about, and comply with, all applicable laws and regulations.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus has been prepared in connection with the Rights Issue. The Company has prepared and published an information document in respect of the Rights Issue, which is available on the Company's website (https://investors.scibase.se).
This press release does not identify, and does not purport to identify, any risks (direct or indirect) that may be associated with an investment in the Company. The information in this press release is intended only to describe the background to the Rights Issue and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information in this press release.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the "Securities Act") and may not be offered or sold in the United States absent registration, or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction in which such release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require registration, or measures other than those required under Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not relate to historical facts and events, as well as statements relating to the future which, for example, contain expressions such as "anticipates", "intends", "may", "will", "should", "estimates", "believes", "could", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results, financial position, cash flows, plans and expectations regarding the company's operations and management, future growth and profitability, as well as the general economic and regulatory environment and other circumstances affecting the company, many of which are in turn based on further assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which, individually or together, may be material to the company's results or its ability to conduct its operations. Although the Company considers that these assumptions were reasonable when they were made, they are by their nature subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and that may be beyond the Company's control. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Prospective investors should therefore not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly recommended to read those sections of the information document that contain a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements in this press release are valid only as at the date of this press release and may be subject to change without notice.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.
The subscription period in the Rights Issue remains unchanged and runs from 15 September 2026 up to and including 29 September 2026.
Updated timetable for the Rights Issue
Subscription period
15-29 September 2026
Trading in subscription rights
16-24 September 2026
Trading in paid subscribed shares (BTA)
16 September - 16 October 2026
Expected announcement of the outcome of the Rights Issue
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
Important information:
The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law, and persons in the jurisdictions in which this press release has been made public or distributed should inform themselves about, and comply with, such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with the applicable rules in each jurisdiction.
The availability of the Rights Issue to holders not resident in Sweden may be affected by the legislation of the relevant jurisdiction in which they are located. Holders not resident in Sweden should inform themselves about, and comply with, all applicable laws and regulations.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document in respect of the Rights Issue. The information document is available on the Company's website (https://investors.scibase.se).
This press release does not identify, and does not purport to identify, any risks (direct or indirect) that may be associated with an investment in the Company. The information in this press release is intended only to describe the background to the Rights Issue and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information in this press release.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the "Securities Act"), and may not be offered or sold in the United States absent registration, or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction in which such release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require registration, or measures other than those required under Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not relate to historical facts and events, as well as statements relating to the future which, for example, contain expressions such as "anticipates", "intends", "may", "will", "should", "estimates", "believes", "could", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results, financial position, cash flows, plans and expectations regarding the company's operations and management, future growth and profitability, as well as the general economic and regulatory environment and other circumstances affecting the company, many of which are in turn based on further assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which, individually or together, may be material to the company's results or its ability to conduct its operations. Although the Company considers that these assumptions were reasonable when they were made, they are by their nature subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and that may be beyond the Company's control. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Prospective investors should therefore not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly recommended to read those sections of the information document that contain a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements in this press release are valid only as at the date of this press release and may be subject to change without notice.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE ADDITIONAL PROSPECTUSES, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE FOR FURTHER INFORMATION.
In connection with the Rights Issue, the Company has prepared an information document (the"Information Document"). The Information Document is not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC, as amended (the "Prospectus Regulation") and has not been approved or reviewed by any regulatory authority in any jurisdiction. Nor does the Information Document constitute an exemption document in the form prescribed in accordance with the requirements of Annex IX to Article 1(4)(db) of the Prospectus Regulation.
SciBase today announces that the Information Document has been published and is available on the Company's website, http://www.scibase.com/, and will also be available on Bergs Securities' website, https://www.bergssecurities.se/.
Subscription forms will be available on the Company's website and will also be available on Bergs Securities' website, https://www.bergssecurities.se/.
Indicative timetable for the Rights Issue
Trading in subscription rights
15-24 September 2026
Subscription period
15-29 September 2026
Trading in paid subscribed shares (BTA)
15 September - 16 October 2026
Expected publication of the outcome of the Rights Issue
1 October 2026
Advisers
SciBase has engaged Bergs Securities and Birchtree Advisory as financial advisers and BAHR as legal adviser in connection with the Rights Issue. Bergs Securities is also acting as issuing agent in connection with the Rights Issue.
For further information, please contact:
Jesper Høiland, Chairman of the Board, telephone +45 612 207 30
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com. For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases
Important information:
The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law, and persons in the jurisdictions in which this press release has been made public or distributed should inform themselves about, and comply with, such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with the applicable rules in each jurisdiction.
The availability of the Rights Issue to holders not resident in Sweden may be affected by the legislation of the relevant jurisdiction in which they are located. Holders not resident in Sweden should inform themselves about, and comply with, all applicable laws and regulations.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for any securities in SciBase in any jurisdiction, either from SciBase or from anyone else. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document in respect of the Rights Issue. The information document is available on the Company's website (https://investors.scibase.se).
This press release does not identify, and does not purport to identify, any risks (direct or indirect) that may be associated with an investment in the Company. The information in this press release is intended only to describe the background to the Rights Issue and does not purport to be complete or exhaustive. No representation is made as to the accuracy or completeness of the information in this press release.
This press release does not constitute an offer of, or an invitation to, acquire or subscribe for securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended from time to time (the "Securities Act"), and may not be offered or sold in the United States absent registration, or an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction in which such release, publication or distribution of this information would be unlawful or where such action is subject to legal restrictions or would require registration, or measures other than those required under Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation.
Forward-looking statements
Matters discussed in this press release may contain forward-looking statements. Forward-looking statements are all statements that do not relate to historical facts and events, as well as statements relating to the future which, for example, contain expressions such as "anticipates", "intends", "may", "will", "should", "estimates", "believes", "could", "plans", "continues", "potential", "estimates", "forecasts", "known" or similar expressions. In particular, these statements relate to future results, financial position, cash flows, plans and expectations regarding the company's operations and management, future growth and profitability, as well as the general economic and regulatory environment and other circumstances affecting the company, many of which are in turn based on further assumptions, such as the absence of changes in existing political, legal, tax, market or economic conditions or in applicable laws (including, but not limited to, accounting principles, accounting methods and tax policies), which, individually or together, may be material to the company's results or its ability to conduct its operations. Although the Company considers that these assumptions were reasonable when they were made, they are by their nature subject to significant known and unknown risks, uncertainties, contingencies and other important factors that are difficult or impossible to predict and that may be beyond the Company's control. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in such forward-looking statements. Prospective investors should therefore not place undue reliance on the forward-looking information contained herein, and prospective investors are strongly recommended to read those sections of the information document that contain a more detailed description of factors that may affect the Company's business and the market in which the Company operates. The information, opinions and forward-looking statements in this press release are valid only as at the date of this press release and may be subject to change without notice.
